No Data
Hongri Pharmaceutical: 2024 Annual Results Forecast
Is Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) A Risky Investment?
Tianjin Chase Sun Pharmaceutical (300026.SZ): plans to cancel the equity investment Fund in the jointly held company Tianjin Tianyi Biomedical.
On December 26, Gelonghui reported that Tianjin Chase Sun Pharmaceutical (300026.SZ) announced that the Board of Directors agreed to cancel its investment in Tianjin Tianyi Biomedical Private Equity Fund Co., Ltd. (referred to as "Tianyi Fund"), and authorized the company's management to handle the relevant liquidation and cancellation matters in accordance with the law.
Tianjin Chase Sun Pharmaceutical (300026.SZ): No CRO or CXO Business at the moment.
On December 12, at the investor interaction platform, Tianjin Chase Sun Pharmaceutical (300026.SZ) stated that the main Business it engages in can be roughly divided into Traditional Chinese Medicine granules, finished drugs, medical instruments, raw and auxiliary materials, healthcare services, and intelligent supply chain for drugs and medical devices, with no CRO or CXO Business at present.
Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Tianjin Chase Sun Pharmaceutical (300026.SZ): There is currently no layout for the traditional chinese medicine industry chain and traditional chinese medicine diagnosis and treatment services in xiong'an.
Gelonghui, November 28丨tianjin chase sun pharmaceutical (300026.SZ) stated on the investor interaction platform that there is currently no layout for the traditional chinese medicine industry chain and traditional chinese medicine diagnosis and treatment service business in xiong'an.
The One-year Shareholder Returns and Company Earnings Persist Lower as Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Stock Falls a Further 6.1% in Past Week
